| |
About Us
P2F is the website for both the direct consulting services of Simon
Youlton, its Senior Partner and a portal for P2F to contract out
expertise from any of its associates and contacts with bespoke expertise
according to project needs.
| |
 |
 |
| |
|
Simon
Youlton - Senior Partner |
| |
|
|
Prior to setting up PhaseIIFace Partners in September 2008 Simon
has accumulated a 15 year career in sales in marketing in life sciences
companies and a ten year career in international technology transfer
working with cancer institutes all over the world.
A snap shot of experiences includes:
- Being a Board Member of several life science companies;
- Being a Management Team Member for the worlds largest cancer
charity and non-profit private funder of cancer research whilst
serving in the tech transfer and drug development company Cancer
Research Technology Ltd.
- Being one of three Managers who instigated a management buy-out
of a UK division of a Swiss life science & device company;
- Being a founding member of the 2002 post merger (ICRF/CRC) translational
funding committee (CRUK Discovery Committee) set up to receive
and review academic translational awards and review the drug development
activities of CRT;
- Instigating and developing European networks of partners from
academic organisations and setting up offices and operations in
USA (Boston).
- Developing a network of contacts across Europe and USA within
biotech and Pharmaceutical Co’s for licensing and collaborations.
- Working closely with pre-clinical and clinical development teams
and advising on development decisions.
- Formulating and co-ordinating a novel CRUK translational medicine
initiatives launched in 2008 to set up national multi-disciplinary
collaboration teams across academia to catalyse involvement and
sponsorship from pharmaceutical industry. Themes include cellular
senescence, the histone code and cancer stem cells;
- Drafting and advising on a number of biotech start-up business
plans and identifying and achieving seed and series A funding.
Companies have included therapeutics, device and service based
start-ups and have been located in the UK and Europe;
- Being invited to join as a member of SAB for Bloomsbury Bioseed
Science Foundation
- Being invited to speak at various international conferences
around technology transfer models and best practices in medical
licensing, intellectual property and setting up tech transfer
offices. Meetings held across Europe (ASTP and others) and USA
(AUTM);
- Contributing to Biotech DTI trade missions abroad (USA and Japan);
- Being a voluntary professional representative sitting on the
Surrey, West Sussex & Hampshire Cancer Partnership Research
group which was a consumer /professional regional NCRN panel to
integrate clinical research with the patients and the public;
- Negotiating and drafting major Licenses, collaborations, settlements,
clinical trial agreements, technology transfer retainers and FSA/investment
documents for spin-outs. Major deals included Small Molecules
/ Biologicals / RNAi platform/ validated targets / platforms /
combination therapies / animal models in oncology (and inflammatory
disorders) and to a smaller degree medical devices.
- Chaperoning to maturity technologies that have formed 4 spin
out companies, the last of which I was an active board member
for over 3 years having secured $4.5m series A funding from US
investors in 2005
- Concluding deals of up to seven figure up-fronts.
- Managing technology transfer and sales and marketing teams of
up to 15 staff
- Being a co-ordinator on an EC framework grant concerning technology
transfer in Europe and having successfully applied for a DTI Smart
award.
I am currently studying part time for a LLM law degree specialising
in Company Law and Intellectual Property Law and Technology. This
is a University of London external post graduate course.
| |
 |
| |
S
Youlton on 'professors' panel for Catalan sponsored biotech
entrepreneurship
course in Barcelona |
| |
|
|
